Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00141336 |
To evaluate the long-term safety and tolerability of pregabalin in patients with partial seizures.
Condition | Intervention | Phase |
---|---|---|
Seizure Disorder, Partial |
Drug: Pregabalin |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Pregabalin BID Open-Label Add-On Trial: An Open-Label, Multicenter Follow-On Study to Determine Long-Term Safety and Efficacy in Patients With Partial Seizures. |
Ages Eligible for Study: | 12 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Study ID Numbers: | 1008-035 |
Study First Received: | August 30, 2005 |
Last Updated: | December 28, 2006 |
ClinicalTrials.gov Identifier: | NCT00141336 |
Health Authority: | United States: Food and Drug Administration |
Epilepsies, Partial Signs and Symptoms Epilepsy Seizures |
Pregabalin Neurologic Manifestations Central Nervous System Diseases Brain Diseases |
Sensory System Agents Therapeutic Uses Physiological Effects of Drugs Nervous System Diseases Peripheral Nervous System Agents |
Analgesics Central Nervous System Agents Anticonvulsants Pharmacologic Actions |